Neuropathic Ocular Pain Market to Rise by 2034 | Novartis AG, SALVAT, AbbVie, Bausch & Lomb Incorporated, Kala Pharmaceuticals, Spectra Vision Care., Alcon Laboratories, OKYO Pharma Limited, Ocular Therapeutix, IACTA Pharmaceuticals, Sun Pharmaceutical In

DelveInsight's "Neuropathic Ocular Pain Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Neuropathic Ocular Pain, historical and forecasted epidemiology as well as the Neuropathic Ocular Pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Neuropathic Ocular Pain market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Neuropathic Ocular Pain market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Neuropathic Ocular Pain treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Neuropathic Ocular Pain market.

Request for a Free Sample Report @ https://www.delveinsight.com/sample-request/neuropathic-ocular-pain-nop-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key highlights from the neuropathic ocular pain market report:

In 2023, the total number of eye disorders and surgeries across the seven major markets (7MM) reached approximately 18.465 million cases. This statistic underscores the substantial burden of ocular conditions and the pressing need for medical interventions in these regions, emphasizing critical areas for eye health management and treatment strategies.

Within this context, the total cases of Neuropathic Ocular Pain (NOP) associated with various eye disorders and surgeries were around 3.075 million in the 7MM, with projections indicating an increase by 2034.

In the United States, the incidence rates for various eye disorders in 2023 included severe Dry Eye Disease at about 8%, refractive surgeries nearing 13%, cataract surgery at approximately 57%, and other conditions-such as infections, systemic diseases, and ocular surface disorders-at 22%. These statistics highlight the prevalence of these conditions and the ongoing need for targeted healthcare interventions and management strategies in the ophthalmic field.

The NOP market in 2023 is characterized by off-label therapies that provide only temporary, nonspecific relief, resulting in a market size of approximately USD 100 million across the 7MM. This market size is expected to grow at a significant compound annual growth rate (CAGR) of 5.2%, driven by the anticipated launch of emerging therapies during the study period from 2020 to 2034.

The neuropathic ocular pain market is fueled by increased awareness, demand for effective targeted therapies, and a rising incidence of related ocular disorders. Key drivers include advancements in drug development and greater recognition of the condition's impact on quality of life. However, challenges remain, such as limited treatment options, diagnostic complexities, high development costs, and insufficient research, which impede effective management and market progress.

In February 2024, OKYO Pharma received FDA approval for an Investigational New Drug (IND) application for OK-101, marking a significant milestone as the first drug targeting neuropathic corneal pain (NCP), an area with substantial unmet need. NCP is classified as an orphan disease, and this approval highlights OK-101's potential to address both NCP and NOP, conditions currently lacking FDA-approved treatments.

Neuropathic Ocular Pain Overview

Neuropathic ocular pain (NOP) is a complex and often debilitating condition characterized by chronic pain in and around the eye. It arises from damage to the nerves that transmit pain signals, leading to sensations that can be sharp, burning, or throbbing. NOP can significantly affect a patient's quality of life and may be associated with other ocular or systemic conditions.

Causes
Neuropathic ocular pain can be caused by a variety of factors, including:

Nerve Damage: Injury or damage to the trigeminal nerve, which is responsible for sensation in the face and eye.
Ocular Conditions: Conditions such as dry eye syndrome, corneal abrasions, or herpes simplex virus infections can lead to nerve injury and pain.
Surgery or Trauma: Previous eye surgeries or traumatic injuries to the eye can result in neuropathic pain.
Systemic Diseases: Conditions like diabetes, multiple sclerosis, or shingles (post-herpetic neuralgia) may contribute to nerve damage and resultant pain.
Neuropathies: Peripheral neuropathies or central nervous system disorders can also lead to ocular pain.
Signs and Symptoms
Patients with neuropathic ocular pain may experience a range of symptoms, including:

Chronic Eye Pain: Often described as burning, stabbing, or throbbing.
Sensitivity to Light: Increased sensitivity (photophobia) can occur, making it uncomfortable to be in bright environments.
Tearing or Dryness: Changes in tear production may lead to either excessive tearing or dryness (keratoconjunctivitis sicca).
Visual Disturbances: Some patients may report blurred vision or other visual disturbances.
Headaches: Associated headaches may accompany ocular pain.
Diagnosis
Diagnosing neuropathic ocular pain typically involves a comprehensive evaluation, which may include:

Medical History: Detailed assessment of symptoms, medical history, and any prior ocular conditions or injuries.
Ophthalmic Examination: Comprehensive eye examination to evaluate eye health, corneal sensation, and tear production.
Neurological Assessment: Examination of nerve function and any potential systemic causes of neuropathic pain.
Imaging Studies: In some cases, imaging studies like MRI may be utilized to rule out structural abnormalities or lesions.
Treatment Options
Managing neuropathic ocular pain often requires a multidisciplinary approach, and treatment options may include:

Medications:

Antidepressants: Tricyclic antidepressants (e.g., amitriptyline) can help alleviate pain.
Anticonvulsants: Medications like gabapentin or pregabalin may be effective in managing neuropathic pain.
Topical Anesthetics: Short-term use of topical medications may provide relief.
Ocular Lubrication: Artificial tears or ointments can help manage dryness and irritation.

Physical Therapy: Some patients benefit from ocular physical therapy to improve eye function and alleviate pain.

Nerve Blocks: In certain cases, nerve blocks may be used to reduce pain.

Alternative Therapies: Acupuncture, mindfulness techniques, and cognitive behavioral therapy may also provide relief.

Management of Underlying Conditions: Treating any underlying systemic or ocular conditions contributing to pain can be beneficial.
Neuropathic ocular pain is a complex condition that requires careful diagnosis and management. Collaboration between ophthalmologists, neurologists, and pain specialists is essential to develop an effective treatment plan tailored to each patient's needs. Early intervention and a multidisciplinary approach can help improve quality of life for those affected by this condition.

Learn more about Neuropathic Ocular Pain, treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/report-store/neuropathic-ocular-pain-nop-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Neuropathic Ocular Pain Market

Current treatments for neuropathic ocular pain (NOP) include both pharmacological and non-pharmacological approaches. Pharmacological options consist of topical anesthetics like lidocaine and tetracaine, which temporarily numb the corneal surface for relief. Nerve growth factor (NGF) inhibitors, such as cenegermin, are also utilized to promote corneal healing and alleviate pain by targeting underlying nerve damage. Additionally, off-label prescriptions of antidepressants like amitriptyline and anticonvulsants such as gabapentin can help manage chronic pain through their central pain-modulating effects.

Non-pharmacological treatments involve corneal neurostimulation techniques, including intense pulsed light therapy and autologous serum eye drops, which aim to support nerve repair and reduce pain. Lubricating eye drops and ointments are also beneficial, keeping the corneal surface moist to minimize discomfort. However, many of these treatments offer only partial or temporary relief, highlighting the need for more effective, long-term solutions.

The pipeline for NOP treatments remains notably limited, with few drug candidates currently in development, reflecting a significant gap in addressing this condition. Despite ongoing research, the absence of innovative therapies means that effective long-term solutions for NOP are scarce, emphasizing the urgent need for advancements in this area.

Nevertheless, the pharmaceutical landscape is poised for evolution, with ongoing clinical trials investigating novel treatments, including OK-101 and other potential drugs. Although curative options are lacking, continued advancements in research and a comprehensive approach are essential to meet the unmet needs in NOP treatment.

With sustained research efforts and dedication, there is hope for the development of more effective treatments and, ultimately, a cure for this challenging condition. According to DelveInsight, the NOP market across the seven major markets (7MM) is projected to grow significantly during the study period from 2020 to 2034.

Request a sample and discover more about the report offerings at:
https://www.delveinsight.com/sample-request/neuropathic-ocular-pain-nop-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Neuropathic Ocular Pain Epidemiology

In DelveInsight's assessment, the incidence of various eye disorders in Japan in 2023 reached approximately 3.352 million cases. This total includes severe Dry Eye Disease at 36%, post-operative complications at 13%, cataract surgeries at 29%, and other conditions, such as infections, systemic diseases, and various ocular surface disorders, at 21%. These statistics emphasize the prevalence of these eye conditions and the urgent need for targeted healthcare interventions and effective management strategies within the ophthalmic sector.

In the EU4 and the UK, there were around 1.625 million cases of Neuropathic Ocular Pain in the 7MM in 2023. Among European countries, Italy reported the highest number of cases, with approximately 535 thousand, followed by France with nearly 350 thousand cases.

DelveInsight's projections for 2023 indicate that the EU4 and the UK account for 44% of the total cases of various eye disorders and surgeries across the 7MM, exceeding the US at 38% and Japan at 18%. These percentages are expected to increase during the forecast period from 2024 to 2034, suggesting a projected rise in the prevalence of these conditions.

Explore more about Neuropathic Ocular Pain Epidemiology at: https://www.delveinsight.com/report-store/neuropathic-ocular-pain-nop-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Neuropathic Ocular Pain Drugs Uptake

This section evaluates the expected market uptake of potential new drugs scheduled for release between 2020 and 2034. It provides details on the anticipated launch year for each drug, their projected peak market share percentage, and the estimated timeframe to achieve that peak. Additionally, the analysis outlines the expected uptake patterns for these therapies.

In the neuropathic ocular pain (NOP) market across the seven major markets (7MM), the US holds the largest share at 71%, followed by the EU4 and the UK at 23%. Japan accounts for the smallest market share, representing just 6%. This distribution highlights the US as the primary market for NOP, with significant but smaller markets in Europe and a minimal presence in Japan.

Emerging Neuropathic Ocular Pain Drugs

OK-101: OKYO Pharma Limited

OK-101, developed by OKYA Pharma, represents a promising therapeutic approach for neuropathic corneal pain (NCP), a condition characterized by chronic pain in the cornea in response to stimuli that are normally non-painful. OK-101 is designed to target the underlying pathophysiological mechanisms of NCP, aiming to provide relief by addressing the specific nerve pain pathways involved in this disorder.

OK-101 is a selective ion channel modulator designed to address neuropathic corneal pain (NOP) by altering nerve signal transmission. This novel approach aims to provide more effective and targeted relief compared to existing treatments, which often offer only temporary relief for NOP. As clinical trials advance, OK-101 could significantly enhance management strategies for NOP, addressing a critical gap in effective, long-lasting pain relief.

Recently Novartis finalized the divestment of its 'front of eye' ophthalmology assets, including investigational medicine SAF312 (libvatrep), to Bausch + Lomb for an upfront cash payment of USD 1.75 billion. Despite this transaction, SAF312 has been removed from Bausch + Lomb's pipeline, and its future availability remains uncertain. Consequently, forecasting for SAF312 is not feasible at this time.

Request for a sample report to understand more about the Neuropathic Ocular Pain pipeline development activities at: https://www.delveinsight.com/sample-request/neuropathic-ocular-pain-nop-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Neuropathic Ocular Pain Therapeutics Assessment

Major pharma companies such as Novartis AG, SALVAT, AbbVie, Bausch & Lomb Incorporated, Kala Pharmaceuticals, Spectra Vision Care., Alcon Laboratories, OKYO Pharma Limited, Ocular Therapeutix, IACTA Pharmaceuticals, Sun Pharmaceutical Industries Ltd., AERIE PHARMACEUTICALS, INC, Optocred Pharmaceuticals, BRIM Biotechnology, and others are working proactively in the Neuropathic Ocular Pain Therapeutics market to develop novel therapies which will drive the Neuropathic Ocular Pain treatment markets in the upcoming years.

Learn more about the emerging therapies & key companies at: https://www.delveinsight.com/report-store/neuropathic-ocular-pain-nop-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Neuropathic Ocular Pain Report Key Insights

1. Neuropathic Ocular Pain Patient Population
2. Neuropathic Ocular Pain Market Size and Trends
3. Key Cross Competition in the Neuropathic Ocular Pain Market
4. Neuropathic Ocular Pain Market Dynamics (Key Drivers and Barriers)
5. Neuropathic Ocular Pain Market Opportunities
6. Neuropathic Ocular Pain Therapeutic Approaches
7. Neuropathic Ocular Pain Pipeline Analysis
8. Neuropathic Ocular Pain Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Neuropathic Ocular Pain Market

Table of Contents

1. Key Insights
2. Executive Summary
3. Neuropathic Ocular Pain Competitive Intelligence Analysis
4. Neuropathic Ocular Pain Market Overview at a Glance
5. Neuropathic Ocular Pain Disease Background and Overview
6. Neuropathic Ocular Pain Patient Journey
7. Neuropathic Ocular Pain Epidemiology and Patient Population
8. Neuropathic Ocular Pain Treatment Algorithm, Current Treatment, and Medical Practices
9. Neuropathic Ocular Pain Unmet Needs
10. Key Endpoints of Neuropathic Ocular Pain Treatment
11. Neuropathic Ocular Pain Marketed Products
12. Neuropathic Ocular Pain Emerging Therapies
13. Neuropathic Ocular Pain Seven Major Market Analysis
14. Attribute Analysis
15. Neuropathic Ocular Pain Market Outlook (7 major markets)
16. Neuropathic Ocular Pain Access and Reimbursement Overview
17. KOL Views on the Neuropathic Ocular Pain Market
18. Neuropathic Ocular Pain Market Drivers
19. Neuropathic Ocular Pain Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Get the Detailed TOC of the Neuropathic Ocular Pain Market report here: https://www.delveinsight.com/report-store/neuropathic-ocular-pain-nop-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Us:

Kritika Rehani
info@delveinsight.com
+14699457679
www.delveinsight.com

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.